

OFF to ON: Emerging Strategies to Manage OFF Episodes in Patients with Parkinson's Disease

References

1. Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease. *Mov Disord Clin Pract*. 2017;4(1):78-83. doi:10.1002/mdc3.12350
2. Parkinson's Foundation. What is Parkinson's? Accessed December 24, 2020. <https://www.parkinson.org/understanding-parkinsons/what-is-parkinsons>
3. Parkinson's Foundation. Managing PD mid-stride: a treatment guide to Parkinson's disease. Accessed December 24, 2020. <https://www.parkinson.org/sites/default/files/attachments/MidStride.pdf>
4. Reichmann H, Poewe W, Ebersbach G, Müller T. Levodopa-related 'wearing off' in Parkinson's disease: current therapeutic options professor. *EMJ Neurol*. 2017;5(suppl 1):2-10.
5. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? *Eur Neurol*. 2010;63(5):257-266. doi:10.1159/000300647
6. Martínez-Fernández R, Schmitt E, Martinez-Martin P, Krack P. The hidden sister of motor fluctuations in Parkinson's disease: a review on nonmotor fluctuations. *Mov Disord*. 2016;31(8):1080-1094. doi:10.1002/mds.26731
7. Stocchi F, Antonini A, Barone P, et al. Early detection of wearing off in Parkinson disease: the DEEP study. *Parkinsonism Relat Disord*. 2014;20(2):204-211. doi:10.1016/j.parkreldis.2013.10.027
8. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. *Brain*. 2000;123(Pt 11):2297-2305. doi:10.1093/brain/123.11.2297
9. DeMaagd G, Philip A. Parkinson's disease and its management: Part 4: treatment of motor complications. *P & T*. 2015;40(11):747-773.
10. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. *Drugs*. 2016;76(7):759-777. doi:10.1007/s40265-016-0566-3
11. Parkinson's Foundation. COVID-19 & Parkinson's. Accessed December 24, 2020. <https://www.parkinson.org/understanding-parkinsons/covid-19>
12. Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Narayanan NS. Coronavirus disease 2019 case fatality and Parkinson's disease. *Mov Disord*. 2020;35(11):1914-1915. doi:10.1002/mds.28325
13. Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study. *Mov Disord*. 2020;35(8):1287-1292. doi:10.1002/mds.28170
14. Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. *Postgrad Med J*. 2004;80(946):452-458. doi:10.1136/pgmj.2003.013912
15. Pappert E, deGruyther N, Agro A. Treatment of OFF episodes in Parkinson's disease: an evaluation of patient and caregiver insights [abstract]. *Mov Disord*. 2016;31(suppl 2). Accessed December 24,

OFF to ON: Emerging Strategies to Manage OFF Episodes in Patients with Parkinson's Disease

2020. <https://www.mdsabstracts.org/abstract/treatment-of-off-episodes-in-parkinsons-disease-an-evaluation-of-patient-and-caregiver-insights/>

16. Stocchi F, Coletti C, Bonassi S, Radicati FG, Vacca L. Early-morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time-to-ON Questionnaire. *Eur J Neurol*. 2019;26(5):821-826. doi:10.1111/ene.13895
17. Nonnekes J, Snijders AH, Nutt JG, Deuschl G, Giladi N, Bloem BR. Freezing of gait: a practical approach to management. *Lancet Neurol*. 2015;14(7):768-778. doi:10.1016/S1474-4422(15)00041-1
18. Rastgardani T, Armstrong MJ, Gagliardi AR, Marras C. Understanding, impact, and communication of "Off" periods in Parkinson's disease: a scoping review. *Mov Disord Clin Pract*. 2018;5(5):461-470. doi:10.1002/mdc3.12672
19. Levit AV, Zebendon C, Walter L, O'Donnell P, Marras C. Communication gaps about OFF periods between physicians and patients with Parkinson's disease: a patient-physician dialogue analysis. *Research and Reviews in Parkinsonism*. 2019;9:3-8.
20. Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. *Neurotherapeutics*. 2014;11(1):78-91. doi:10.1007/s13311-013-0238-x
21. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. *Mov Disord*. 2005;20(2):224-230. doi:10.1002/mds.20279
22. Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Neurol*. 2020;19(2):135-144. doi:10.1016/S1474-4422(19)30396-5
23. LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Neurol*. 2019;18(2):145-154. doi:10.1016/S1474-4422(18)30405-8
24. Fox SH, Katzenschlager R, Lim S-Y, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. *Mov Disord*. 2018;33(8):1248-1266. doi:10.1002/mds.27372
25. Hauser RA. Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. *Evid Based Med*. 2015;20(1):17. doi:10.1136/ebmed-2014-110115
26. Margolesky J, Singer C. Extended-release oral capsule of carbidopa-levodopa in Parkinson disease. *Ther Adv Neurol Disord*. 2018;11:1756285617737728. doi:10.1177/1756285617737728
27. Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary®, an extended-release capsule formulation of carbidopa-levodopa. *Clin Pharmacokinet*. 2017;56(9):999-1014. doi:10.1007/s40262-017-0511-y

OFF to ON: Emerging Strategies to Manage OFF Episodes in Patients with Parkinson's Disease

28. Duopa (carbidopa and levodopa) enteral suspension. Prescribing information. AbbVie, Inc; January 2015. Accessed December 24, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203952s000lbl.pdf
29. Parkinson's Foundation. PD and medication: what's new? May 3, 2019. Accessed December 24, 2020. <https://www.parkinson.org/blog/tips/pd-and-medication-whats-new>
30. Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. *CMAJ*. 2019;191(36):E989-E1004. doi:10.1503/cmaj.181504
31. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. *Mov Disord*. 2004;19(9):997-1005. doi:10.1002/mds.20243
32. Dezsai L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson's disease. *CNS Neurol Disord Drug Targets*. 2017;16(4):425-439. doi:10.2174/1871527316666170124165222
33. Binde CD, Tvette IF, Gåsemeyr J, Natvig B, Klemp M. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. *Br J Clin Pharmacol*. 2018;84(9):1917-1927. doi:10.1111/bcp.13651
34. Elmer LW, Juncos JL, Singer C, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson's disease. *CNS Drugs*. 2018;32(4):387-398. doi:10.1007/s40263-018-0498-4
35. Apokyn (apomorphine hydrochloride injection) for subcutaneous use. Prescribing information. US WorldMeds, LLC; April 2020. Accessed December 24, 2020. https://www.apokyn.com/sites/all/themes/apokyn/content/resources/Apokyn_PI.pdf
36. Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. *Clin Ther*. 2005;27(11):1710-1724. doi:10.1016/j.clinthera.2005.11.016
37. Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol*. 2015;14(6):625-639. doi:10.1016/S1474-4422(15)00007-1
38. Fidler B. Sunovion crowds a new group of Parkinson's drugs, with uncertain sales prospects. BioPharma Dive. May 22, 2020. Accessed December 24, 2020. <https://www.biopharmadive.com/news/parkinsons-drugs-sunovion-fda-approval/578514/>
39. Nourianz (istradefylline). Prescribing information. Kyowa Kirin Inc; May 2020. Accessed December 24, 2020. <https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf>
40. Torti M, Vacca L, Stocchi F. Istradefylline for the treatment of Parkinson's disease: is it a promising strategy? *Expert Opin Pharmacother*. 2018;19(16):1821-1828. doi:10.1080/14656566.2018.1524876
41. Ongentys (opicapone). Prescribing information. Neurocrine Biosciences, Inc; April 2020. Accessed December 24, 2020. <https://www.neurocrine.com/assets/ONGENTYS-PI.pdf>

OFF to ON: Emerging Strategies to Manage OFF Episodes in Patients with Parkinson's Disease

42. Lees A, Ferreira JJ, Rocha J-F, et al. Safety profile of opicapone in the management of Parkinson's disease. *J Parkinsons Dis*. 2019;9(4):733-740. doi:10.3233/JPD-191593
43. Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. *JAMA Neurol*. 2017;74(2):197-206. doi:10.1001/jamaneurol.2016.4703
44. Inbrija (levodopa inhalation powder). Prescribing information. Acorda Therapeutics, Inc; August 2018. Accessed December 24, 2020. <https://www.inbrija.com/prescribing-information.pdf>
45. Lopes JM. Inbrija approved in US to treat off periods in Parkinson's patients on carbidopa/levodopa. January 10, 2019. Accessed December 24, 2020. <https://parkinsonsnewstoday.com/2019/01/10/fda-approves-inbrija-treatment-off-periods/>
46. Patel AB, Jimenez-Shahed J. Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date. *Neuropsychiatr Dis Treat*. 2018;14:2955-2964. doi:10.2147/NDT.S147633
47. Hauser RA, Isaacson SH, Ellenbogen A, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. *Parkinsonism Relat Disord*. 2019;64:175-180. doi:10.1016/j.parkreldis.2019.03.026
48. Grosset DG, Dhall R, Gurevich T, et al. Inhaled levodopa in Parkinson's disease patients with OFF periods: a randomized 12-month pulmonary safety study. *Parkinsonism Relat Disord*. 2020;71:4-10. doi:10.1016/j.parkreldis.2019.12.012
49. Kynmobi (apomorphine hydrochloride). Prescribing information. Sunovion Pharmaceuticals Inc; May 2020. Accessed December 24, 2020. <https://www.kynmobi.com/Kynmobi-Prescribing-Information.pdf>
50. Practical Neurology. FDA approves apomorphine sublingual film for treatment of OFF periods in Parkinson disease. May 21, 2020. Accessed December 24, 2020. <https://practicalneurology.com/news/fda-approves-apomorphine-sublingual-film-for-treatment-of-off-periods-in-parkinson-disease>
51. Factor S, Ondo W, Isaacson S, Bhargava P, Navia B. A long-term safety, tolerability, and efficacy study of apomorphine sublingual film for on-demand treatment of "OFF" episodes in patients with Parkinson's disease: interim results [abstract]. *Mov Disord*. 2020;35(suppl 1).
52. Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations. *CNS Drugs*. 2019;33(9):905-918. doi:10.1007/s40263-019-00661-z
53. Modi NB, Mittur A, Rubens R, Khanna S, Gupta S. Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules. *Clin Neuropharmacol*. 2019;42(1):4-8. doi:10.1097/WNF.0000000000000314

OFF to ON: Emerging Strategies to Manage OFF Episodes in Patients with Parkinson's Disease

54. Isaacson S, Espay A, Pahwa R, Clinch T, LeWitt P. Safety and efficacy of continuous apomorphine infusion in patients with Parkinson's disease: results from a phase 3, open-label study [abstract]. *Neurology*. 2020;94(15 suppl).
55. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in Parkinson's disease patients with persistent motor fluctuations: a multicentre, double-blind, randomised, placebo-controlled study (TOLEDO study). *Lancet Neurol*. 2018;17(9):749-759. doi:10.1016/S1474-4422(18)30239-4
56. Facheris M, Benesh J, Streit J, Robieson W, Zadikoff C, Standaert D. Safety and tolerability in Parkinson's disease patients treated with a continuous subcutaneous infusion of ABBV-951: design of a 52-week phase 3 study [abstract]. *Neurology*. 2020;94(15 suppl).
57. Espay A, Rascol O, Yardeni T, et al. The Boundless study: an active-controlled, randomized, double-blind, double-dummy phase 3 study of continuous ND0612 infusion in patients with Parkinson's disease experiencing motor fluctuations [abstract]. *Neurology*. 2020;94(15 suppl).
58. American Academy of Neurology. Parkinson's disease quality measurement set update. 2016. Accessed December 24, 2020. https://www.aan.com/siteassets/home-page/policy-and-guidelines/quality/quality-measures/movement-disorders/16parkinsonsclinicianssummary_pg.pdf
59. Neurology Live. Managing OFF episodes in Parkinson disease. Episode 17: advice to community neurologists treating Parkinson disease. December 20, 2019. Accessed December 24, 2020. <https://www.neurologylive.com/view/managing-off-episodes-in-parkinsons-disease?seriesVid=17>
60. AHRQ: Agency for Healthcare Research and Quality. The SHARE approach—essential steps of shared decisionmaking: expanded reference guide with sample conversation starters. April 2014. Accessed December 24, 2020. <https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tool/resource-2.html>